AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04095650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS (Seniors using Technology to Engage in Pain Self-management)
Description: Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
Study NCT04507685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle (Diet and Exercise)
Description: The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week.
Study NCT04507685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle (Diet and Exercise)
Description: The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week.
Study NCT01083004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Using indocyanine green as intraoperative dye
Study NCT01083004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brilliant blue arm
Description: Using brilliant blue as intraoperative dye
Study NCT00715026 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trilogy AB Acetabular Hip Implant System
Description: Total hip replacement with ceramic on ceramic treatment surfaces.
Study NCT01535170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: bovine Lactoferrin
Description: Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
Study NCT01535170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine Lactoferrin
Description: Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
Study NCT00247000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care in a HF clinic vs Home Telehealth Care for HF
Study NCT00552175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride - 40 mg
Description: duloxetine 40 mg taken orally every day
Study NCT00552175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken orally every day
Study NCT00552175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride - 60 mg
Description: duloxetine 60 mg taken orally every day
Study NCT00554359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP (a small interfering RNA)
Description: Single IV injection of experimental drug
Study NCT00554359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single IV injection of saline
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered in accordance with the label or Investigator's discretion
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol will be administered in accordance with the label or Investigator's discretion
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine will be administered in accordance with the label or Investigator's discretion
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paliperidone ER
Description: Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Perphenazine will be administered in accordance with the label or Investigator's discretion
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered in accordance with the label or Investigator's discretion
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Risperidone tablets 1-6 mg per day will be administered orally.
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP1M)
Description: Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
Study NCT02431702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP3M)
Description: Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
Study NCT00721474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib fasting
Study NCT00721474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib fed
Study NCT05348148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Levocetirizine
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study NCT05348148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intranasal Mometasone Furoate with oral Levocetirizine
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study NCT05348148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study NCT01179464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminobiphosphonate
Description: Patients will receive standard intravenous biphosphonate treatment
Study NCT01179464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminobiphosphonate
Description: Patients will receive standard intravenous biphosphonate treatment
Study NCT01179464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg once daily
Study NCT02734160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study NCT02734160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV
Study NCT03506035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Research new biomarker for RA
Description: Analyze T and B cell response against new citrullinated peptides
Study NCT00842738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation
Description: Mindfulness meditation
Study NCT00842738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No meditation
Description: Health care services as usual
Study NCT00842738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: No intervention
Study NCT00202787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-4+cetuximab
Description: Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
Study NCT00202787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
Study NCT03624699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaukos iStent inject®
Description: iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
Study NCT00822757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V710
Description: Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
Study NCT00822757 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
Study NCT00868777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus grafting using allogenic bone
Description: Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
Study NCT04135339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
Study NCT04135339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric exercise.
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
Study NCT04135339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise.
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
Study NCT04327687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Description: 5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
Study NCT04327687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy
Study NCT04327687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy
Study NCT02833012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride Oil
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
Study NCT02833012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
Study NCT02833012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axona
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
Study NCT02833012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
Study NCT03568591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosensory Therapy
Description: Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop smoking
Study NCT00320008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop smoking
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose lowering therapy
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose lowering therapy
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering therapy
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure lowering therapy
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid lowering therapy
Study NCT00320008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid lowering therapy
Study NCT00708500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (SCH 503034)
Description: Boceprevir, 200 mg capsules, 800 mg TID PO
Study NCT00708500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (SCH 54031)
Description: PEG2b 1.5 μg/kg/week subcutaneously (SC)
Study NCT00708500 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon alfa-2b (SCH 54031)
Description: PEG2b 1.5 μg/kg/week subcutaneously (SC)
Study NCT00708500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
Study NCT00708500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
Study NCT00708500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir placebo
Description: Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
Study NCT00708500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Boceprevir placebo
Description: Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
Study NCT03583151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic fluid injection
Description: Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
Study NCT03583151 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection
Description: Solu-medrol
Study NCT03641872 — intervention group
Intervention type: OTHER
Intervention: Standary therapy
Description: Standary therapy for chronic liver disease with ALI and/or AD
Study NCT04756700 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DigiCog (BCCAMS app)
Description: Administered as specified in the treatment arm.
Study NCT04756700 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Konectom Application
Description: Administered as specified in the treatment arm.
Study NCT03120221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample for iodine measurement
Description: Women will be required to give a urine sample for iodine measurement
Study NCT04493021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
Study NCT03885791 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vaginal cryotherapy
Description: Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application.
Study NCT03885791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal cryotherapy
Description: Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application.
Study NCT01722604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brinzolamide 1% ophthalmic suspension
Description: brinzolamide 1% ophthalmic suspension